Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of ginkgetin on liver fibrosis by bulk RNA Sequencing

ABSTRACT: Effects of ginkgetin on liver fibrosis by bulk RNA Sequencing

PROVIDER: PRJNA992421 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25185565_1.fastq.gz	Fastqsanger.gz
	SRR25185565_2.fastq.gz	Fastqsanger.gz
	SRR25185566_1.fastq.gz	Fastqsanger.gz
	SRR25185566_2.fastq.gz	Fastqsanger.gz
	SRR25185567_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Effects of ginkgetin on liver fibrosis by bulk RNA Sequencing

Project description:Ginkgetin could significantly attenuate liver fibrosis in a mouse model induced by TAA, including inhibiting hepatic inflammtion and fibrosis. In addition, the related signaling pathways and gene expression were also downregulated by ginkgetin by bulk RNA Sequencing analysis.

2023-08-03 | GSE236779 | GEO

Effects of ginkgetin on liver fibrosis by bulk RNA Sequencing II

Project description:Ginkgetin could significantly attenuate liver fibrosis in a rat model induced by TAA, including inhibiting hepatic inflammtion and fibrosis. In addition, the related signaling pathways and gene expression were also downregulated by ginkgetin by bulk RNA Sequencing analysis.

2023-09-01 | GSE242212 | GEO

Effects of ginkgetin on liver fibrosis by bulk RNA Sequencing II

Project description:Effects of ginkgetin on liver fibrosis by bulk RNA Sequencing II

| PRJNA1011996 | ENA

Beneficial effects of ginkgetin on nonalcoholic steatohepatitis (NASH) by bulk RNA Sequencing

Project description:Ginkgetin could significantly attenuate NASH in a mouse model induced by high-fat diet, including reducing lipid accumulation in the liver and inhibiting hepatic inflammtion and fibrosis. In addition, the related signaling pathways and gene expression were also downregulated by ginkgetin by bulk RNA Sequencing analysis.

2023-08-03 | GSE235797 | GEO

Effects of ginkgetin on nonalcoholic steatohepatitis (NASH) by single-cell RNA Sequencing (scRNA-Seq).

2023-08-03 | GSE235939 | GEO

Beneficial effects of ginkgetin on nonalcoholic steatohepatitis (NASH) by bulk RNA Sequencing

Project description:Beneficial effects of ginkgetin on nonalcoholic steatohepatitis (NASH) by bulk RNA Sequencing

| PRJNA987645 | ENA

Liver fibrosis

Project description:Liver fibrosis

| PRJNA857444 | ENA

Effects of BLT1 inhibition in a mouse model of liver fibrosis

Project description:Effects of BLT1 inhibition in a mouse model of liver fibrosis

| PRJNA1043143 | ENA

MiR-29a regulates liver fibrosis

Project description:To confirm the mechanism of miR-29a in liver fibrosis healing, we have employed whole genome microarray expression profiling as a discovery platform to identify genes. CCl4 and TAA liver fibrosis model mouse were used for this experiment. After five weeks liver fibrosis induction period, mouse have been observed for one week (1w) or two weeks (2w) and negative control nucleotide (N.C) or miR-29a were injected every 3 days on this period. We used CCl4 1w N.C (n = 1), 1w miR-29a (n = 1), 2w N.C (n = 1), 2w miR-29a (n = 1), and also used TAA model mouse (total n = 8) liver samples for microarray analysis. We can get only one gene (PDGF-c) as a target of miR-29a which relate to liver fibrosis and down-regulated more than 1.5 times in common miR-29a injected group than N.C group. CCl4 and TAA liver fibrosis model mouse were used for this experiment. After five weeks liver fibrosis induction period, mouse have been obserbed for one week (1w) or two weeks (2w) and negative control nucleotide (N.C) or miR-29a were injected every 3 days on this period. We used CCl4 1w N.C (n = 1), 1w miR-29a (n = 1), 2w N.C (n = 1), 2w miR-29a (n = 1), and also used TAA model mouse (total n = 8) liver samples for microarray analysis.

2015-03-31 | E-GEOD-67423 | biostudies-arrayexpress

Factor VII activating protease (FSAP) exerts antifibrotic effects in a mouse model of experimental liver fibrosis

Project description:Background and Rationale: Factor VII activating protease (FSAP) is a circulating serine protease produced in the liver. A single nucleotide polymorphism (G534E, Marburg I, MI-SNP) in the gene encoding FSAP (HABP2) leads to lower enzymatic activity and is associated with enhanced liver fibrosis. FSAP is activated by damaged cells and its substrates include growth factors and haemostasis proteins. We have investigated the progression of liver fibrosis in FSAP deficient mice. Results: Wild type (WT) or FSAP-/- mice were subjected to bile duct ligation (BDL) and assessment of liver fibrosis. FSAP-/- mice showed enhanced liver fibrosis and accumulation of extracellular matrix as determined by Sirius Red staining and hydroxyproline content. FSAP deficient mice exhibited stronger injury as determined by higher necrosis in the liver and circulating liver enzymes. This correlated with expression of markers like M-NM-1-smooth muscle actin, collagen and fibronectin that are markers of stellate cell activation. FSAP-deficient mice exhibited higher expression of PDGF-BB as well as PDGFRM-NM-2 that are strong activators of liver fibrosis. In order to gain more insight into this difference microarray analysis was performed and the pattern of gene expression in WT vs. FSAP-/- mice would indicate that FSAP modulates the inflammatory /immune system. Conclusions: The results with FSAP-/- mice correlates with the human situation where lower FSAP activity, due to the MI SNP, is associated with enhanced liver fibrosis. This strengthens the concept that FSAP is a M-bM-^@M-^\protective factorM-bM-^@M-^] in liver fibrosis. A probable mechanism for this effect is likely to be related to the role of FSAP in the regulation of fibrosis/ inflammation-related processes n the liver. The dataset comprises 12 samples divided into four sample groups each representing a certain treatment group.

2012-09-19 | E-GEOD-36066 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data